Phase 1 trial of dasatinib combined with afatinib for epidermal growth factor receptor- (EGFR-) mutated lung cancer with acquired tyrosine kinase inhibitor (TKI) resistance

Published on Mar 18, 2019in British Journal of Cancer7.64
· DOI :10.1038/S41416-019-0428-3
Ben C. Creelan15
Estimated H-index: 15
,
Jhanelle E. Gray32
Estimated H-index: 32
+ 5 AuthorsEric B. Haura70
Estimated H-index: 70
Sources
Abstract
Bypass activation of Src family kinases can confer resistance to EGFR tyrosine kinase inhibitors (TKIs) based on preclinical models. We prospectively assessed the safety and clinical activity of dasatinib and afatinib in combination for patients with resistant EGFR-mutant lung cancer. An open-label, dose-escalation phase 1/2 trial (NCT01999985) with 2-stage expansion was conducted with 25 lung cancer patients. Dose expansion required activating EGFR mutations and progression following prior EGFR TKI. Patients were 72% Caucasian and received median of 2 prior lines of therapy. Maximum-tolerated dose was 30 mg afatinib with 100 mg dasatinib. New or increased pleural effusions were observed in 56% of patients. No radiologic responses were observed, although several EGFR-mutant TKI-resistant patients (26%) had prolonged stable disease over 6 months. The combination reduced the EGFR mutation and T790M variant allele frequency in cell-free DNA (p < .05). Nonetheless, the threshold for futility was met, based on 6-month progression-free survival. For EGFR TKI-resistant patients, median progression-free survival was 3.7 months (95% confidence interval (CI), 2.3–5.0) and overall survival was 14.7 months (95% CI, 8.5–20.9). The combination had a manageable toxicity profile and in vivo T790M modulation, but no objective clinical responses were observed.
📖 Papers frequently viewed together
8 Authors (Lu Yang, ..., Y. G. Wang)
References21
Newest
#1Chul KimH-Index: 17
#2Stephen V. LiuH-Index: 31
Last. G. GiacconeH-Index: 1
view all 4 authors...
Source
#1Pang-Dian Fan (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 5
#2Giuseppe NarzisiH-Index: 24
Last. Marc Ladanyi (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 7
view all 23 authors...
In ∼30% of patients with EGFR -mutant lung adenocarcinomas whose disease progresses on EGFR inhibitors, the basis for acquired resistance remains unclear. We have integrated transposon mutagenesis screening in an EGFR -mutant cell line and clinical genomic sequencing in cases of acquired resistance to identify mechanisms of resistance to EGFR inhibitors. The most prominent candidate genes identified by insertions in or near the genes during the screen were MET , a gene whose amplification is kno...
Source
#1Ting Fang Lee (NYMU: National Yang-Ming University)H-Index: 1
#2Yu Chi Tseng (NYMU: National Yang-Ming University)H-Index: 1
Last. Cheng-Wen Wu (AS: Academia Sinica)H-Index: 58
view all 6 authors...
Epidermal growth factor receptor (EGFR) mutation is prevalently expressed in lung adenocarcinoma cases and acts as one of the major driving oncogenes. EGFR tyrosine kinase inhibitors (TKIs) have been used in patients with EGFR-mutant as an effective targeted therapy in lung adenocarcinoma, but drug resistance and tumor recurrence inevitably occurs. Recently, Yes-associate protein (YAP) has been reported to promote multiple cancer cell properties, such as promoting cell proliferation, epithelial-...
Source
#1Satomi Watanabe (Kindai University)H-Index: 10
#2Takeshi Yoshida (Kindai University)H-Index: 25
Last. Kazuhiko Nakagawa (Kindai University)H-Index: 101
view all 10 authors...
T790M mutation–selective EGFR tyrosine kinase inhibitors (EGFR-TKI) have demonstrated clinical benefits in non–small cell lung cancer (NSCLC) patients harboring T790M mutation, which is the major cause of resistance to EGFR-TKI. However, their efficacy is limited, possibly due to the emergence of apoptosis resistance in T790M-positive NSCLC. We previously identified Src family kinases as cooncogenic drivers along with T790M and found that the Src inhibitor dasatinib combined with an irreversible...
Source
#1Eiki Ichihara (Vandy: Vanderbilt University)H-Index: 9
#2David Westover (Vandy: Vanderbilt University)H-Index: 8
Last. Christine M. Lovly (Vandy: Vanderbilt University)H-Index: 47
view all 14 authors...
Mutant-selective EGFR tyrosine kinase inhibitors (TKI), such as osimertinib, are active agents for the treatment of EGFR-mutant lung cancer. Specifically, these agents can overcome the effects of the T790M mutation, which mediates resistance to first- and second-generation EGFR TKI, and recent clinical trials have documented their efficacy in patients with EGFR-mutant lung cancer. Despite promising results, therapeutic efficacy is limited by the development of acquired resistance. Here we report...
Source
#1Kenneth S. Thress (AstraZeneca)H-Index: 25
#2Aleksandra Markovets (AstraZeneca)H-Index: 12
Last. Geoffrey R. Oxnard (Harvard University)H-Index: 62
view all 8 authors...
9018Background: Osimertinib, an EGFR T790M-selective tyrosine kinase inhibitor (TKI), provides high and durable response rates in patients (pts) with T790M positive advanced NSCLC whose disease has progressed following EGFR-TKI therapy. We investigated whether changes in the levels of plasma EGFRmutations post-osimertinib treatment are associated with clinical outcome. Methods: We studied pts from the AURA Phase I study (NCT01802632) with acquired resistance to EGFR-TKIs, T790M positive baseline...
Source
#1Pang-Dian Fan (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 5
#2Giuseppe NarzisiH-Index: 24
Last. Marc Ladanyi (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 171
view all 18 authors...
9043Background: Overcoming AR to EGFR TKIs remains challenging, and in many cases the mechanisms are still unclear. To identify novel mechanisms of resistance to EGFR TKIs, we performed a forward genetic screen using transposon mutagenesis in EGFR-mutant lung adenocarcinoma cells. Methods: EGFR TKI-sensitive PC9 cells were co-transfected with plasmids encoding a mutagenic piggyBactransposon and hyperactive piggyBac transposase. Transposon-tagged, afatinib-resistant clones were generated by seque...
Source
#1Hua ZhangH-Index: 12
#2Bin ZhangH-Index: 102
Last. Changli WangH-Index: 21
view all 7 authors...
// Hua Zhang 1,2,3,4,* , Bin Zhang 1,2,3,4,* , Liuwei Gao 1,2,3,4,* , Lianmin Zhang 1,2,3,4 , Kaikai Zhu 2,3,5 , Runfen Cheng 2,3,5 and Changli Wang 1,2,3,4 1 Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China 2 National Clinical Research Center for Cancer, Tianjin, China 3 Key Laboratory of Cancer Prevention and Therapy, Tianjin, China 4 Tianjin Lung Cancer Center, Tianjin, China 5 Department of Pathology, Tianjin Medical University Cancer Instit...
Source
#1José M. PorcelH-Index: 44
#2Ariadna GasolH-Index: 1
Last. Antonieta SaludH-Index: 21
view all 6 authors...
Background and objective The clinical relevance of pleural effusions in lung cancer has seldom been approached systematically. The aim of this study was to determine the prevalence, causes and natural history of lung cancer-associated pleural effusions, as well as their influence on survival. Methods Retrospective review of clinical records and imaging of 556 consecutive patients with a newly diagnosed lung cancer over a 4-year period at our institution. Results Lung cancer comprised 490 non-sma...
Source
#1Kathryn A. Gold (University of Texas MD Anderson Cancer Center)H-Index: 26
#2J. Jack Lee (University of Texas MD Anderson Cancer Center)H-Index: 127
Last. Faye M. Johnson (University of Texas MD Anderson Cancer Center)H-Index: 38
view all 12 authors...
Background. EGFR and Src are frequently activated in non-small cell lung cancer (NSCLC). In preclinical models, combining EGFR and Src inhibition has additive synergistic effects. We conducted a phase I/II trial of the combination of Src inhibitor dasatinib with EGFR inhibitor erlotinib to determine the maximum tolerated dose (MTD), pharmacokinetic drug interactions, biomarkers, and efficacy in NSCLC.
Source
Cited By6
Newest
#1Chul Kim (Georgetown University)H-Index: 17
#2Stephen V. Liu (Georgetown University)H-Index: 31
Last. Giuseppe Giaccone (Cornell University)H-Index: 40
view all 10 authors...
Background: Osimertinib is an effective first-line therapy option for EGFR-mutant NSCLC, but virtually all patients develop resistance. CRIPTO, through Src activation, has been implicated in resistance to EGFR tyrosine kinase inhibitor (EGFR-TKI) therapy. Dasatinib, a Src inhibitor, has shown preclinical synergy with EGFR-TKI therapy. Method: This is a single-arm phase I/II trial of osimertinib and dasatinib in treatment-naive advanced EGFR-mutant NSCLC. A 3+3 design was used in the phase I to e...
Source
#1Ishwar N. Kohale (MIT: Massachusetts Institute of Technology)H-Index: 1
#2Danielle M. Burgenske (Mayo Clinic)H-Index: 2
Last. Forest M. White (MIT: Massachusetts Institute of Technology)H-Index: 60
view all 12 authors...
Human tissue samples commonly preserved as formalin-fixed paraffin-embedded (FFPE) tissues after diagnostic or surgical procedures in the clinic represent an invaluable source of clinical specimens for in-depth characterization of signaling networks to assess therapeutic options. Tyrosine phosphorylation (pTyr) plays a fundamental role in cellular processes and is commonly dysregulated in cancer but has not been studied to date in FFPE samples. Additionally, pTyr analysis that may otherwise info...
Source
#1Junyan Tao (Qingdao University)H-Index: 2
#2Dantong Sun (Qingdao University)H-Index: 4
Last. Helei Hou (Qingdao University)H-Index: 10
view all 3 authors...
Epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) patients benefit from EGFR tyrosine kinase inhibitors (TKIs), while some patients demonstrate a resistance to EGFR-TKIs. In the case reported here, the NSCLC patient harboring an EGFR-sensitive mutation and YES1 amplification was treated with afatinib as first-line therapy, but was found to have progressive disease four weeks later. During subsequent chemotherapy, this patient's disease progressed rapidl...
Source
#1Stefania Belli (University of Naples Federico II)H-Index: 1
#2Daniela Esposito (University of Naples Federico II)H-Index: 3
Last. Roberto Bianco (University of Naples Federico II)H-Index: 52
view all 6 authors...
The proto-oncogene c-Src is a non-receptor tyrosine kinase playing a key role in many cellular pathways, including cell survival, migration and proliferation. c-Src de-regulation has been observed in several cancer types, making it an appealing target for drug discovery efforts. Recent evidence emphasizes its crucial role not only in promoting oncogenic traits, but also in the acquisition and maintenance of cancer resistance to various chemotherapeutic or molecular target drugs. c-Src modulates ...
Source
#1Syed Ahmad (NCCU: North Carolina Central University)H-Index: 7
#2Qingping He (NCCU: North Carolina Central University)H-Index: 1
Last. John E. Scott (NCCU: North Carolina Central University)H-Index: 11
view all 4 authors...
: Triple-negative breast cancer (TNBC) is a very aggressive form of breast cancer with few molecularly targeted therapies. We used a novel unbiased approach to identify higher-order synergistic or enhancer combinations of marketed kinase inhibitor drugs that inhibit cell viability of TNBC cell lines. We mixed all 33 kinase-targeted drugs on the market at the time of this study, which allowed for all possible combinations to exist in the initial mixture. A kinase inhibitor group dropout approach ...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.